Severe. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Certain protease inhibitors may slow down how quickly your liver processes eletriptan.
What might happen:
The amount of eletriptan in your body may increase and cause unwanted side effects such as high blood pressure, a rapid heart beat, chest pain, sweating, nausea, or dizziness.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change one of the medicines that you are taking. If you notice any extra side effects from your eletriptan while taking your protease inhibitor, let your doctor know right away.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Relpax (eletriptan hydrobromide) UK summary of product characteristics. Pfizer Limited September, 2013.
2.Relpax (eletriptan hydrobromide) US prescribing information. Pfizer Inc. November 27, 2013.
3.Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir) prescribing information. Gilead Sciences, Inc. October, 2013.
4.Incivek (telaprevir) US prescribing information. Vertex Pharmaceuticals Incorporated October, 2013.
5.Victrelis (boceprevir) US prescribing information. Schering Corporation July, 2014.
6.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..
7.Frova (frovatriptan) US prescribing information. Endo Pharmaceuticals October, 2013.
8.Imitrex Tablets (sumatriptan) US prescribing information. GlaxoSmithKline March, 2012.
9.Zomig (zolmitriptan) US prescribing information. AstraZeneca Pharmaceuticals LP September, 2012.
10.Yu AM. Indolealkylamines: biotransformations and potential drug-drug interactions. AAPS J 2008 Jun;10(2):242-53.